Haemonetics Corporation (HAE) Q3 Performance Prompts Baird Model Update, Price Target Falls to $81

Haemonetics Corporation (NYSE:HAE) is among the 15 Innovative Healthcare Stocks to Buy According to Analysts.

Haemonetics Corporation (NYSE:HAE) is among the most innovative healthcare stocks.

TheFly reported on February 6 that Baird lowered its price target for HAE to $81 from $99 while maintaining an Outperform rating. The firm updated its model following the company’s Q3 results and lowered the estimates for certain segments. However, Baird noted that the Plasma business appears to offer upside potential, which provides a possible lever for future growth despite the more conservative outlook.

In contrast, on the same day, Barrington Research raised its price target on Haemonetics Corporation (NYSE:HAE) to $94 from $93 while maintaining an Outperform rating. The update followed a “mixed bag” quarter, but the company provided what Barrington described as solid guidance for fiscal year 2026, supporting confidence in its near-term outlook despite variability in quarterly results.

Haemonetics Corporation (NYSE:HAE) is a global medical technology innovator delivering advanced blood, plasma, and surgical care solutions that improve clinical outcomes and operational efficiency. Its portfolio combines cutting‑edge devices, software, and automation that enhance collection yield, workflow efficiency, and patient safety in hospitals and blood centers worldwide.

While we acknowledge the potential of HAE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Most Profitable Undervalued Stocks to Buy and 11 Best Mining Stocks to Buy According to Wall Street.

Disclosure: None.